Study and Treatment | N | Mean Modal Dose/ Corresponding Daily Dose (mg/day) | PANSS Total LS Mean Change | PANSS Total Effect Sizea(category)b | BPRS Total LS Mean Change | BPRS Total Effect Sizea(category)b |
---|---|---|---|---|---|---|
OLZ LAI Study | ||||||
405 mg/4 weeks olanzapine LAI | 100 | 14.5 | −22.5 | .75 (moderate) | −14.2 | .71 (moderate) |
210 mg/2 weeks olanzapine LAI | 106 | 15.0 | −22.8 | .80 (large) | −14.4 | .77 (moderate) |
300 mg/2 weeks olanzapine LAI | 100 | 21.4 | −24.8 | .88 (large) | −15.4 | .82 (large) |
vs. Placebo | 98 | 0.0 | −8.7 | -- | −6.1 | -- |
Oral Study 1 | ||||||
5 ± 2.5 mg/day olanzapine | 65 | 6.6 | -- | -- | −6.4 | .17 (small) |
10 ± 2.5 mg/day olanzapine | 64 | 11.6 | -- | -- | −12.2 | .50 (moderate) |
15 ± 2.5 mg/day olanzapine | 69 | 16.3 | -- | -- | −15.2 | .67 (moderate) |
15 ± 5.0 mg/day haloperidol | 69 | 16.4 | -- | -- | −12.8 | .57 (moderate) |
vs. Placebo | 68 | 0.0 | -- | -- | −3.7 | -- |
Oral Study 2 | ||||||
5 ± 2.5 mg/day olanzapine | 87 | 6.7 | −21.4 | .17 (small) | −13.4 | .19 (small) |
10 ± 2.5 mg/day olanzapine | 86 | 11.3 | −22.7 | .20 (small) | −13.8 | .19 (small) |
15 ± 2.5 mg/day olanzapine | 89 | 16.4 | −26.7 | .37 (moderate) | −16.4 | .38 (moderate) |
15 ± 5.0 mg/day haloperidol | 81 | 17.6 | −20.0 | .12 (small) | −12.4 | .12 (small) |
vs. 1.0 mg/day olanzapine | 88 | 0.0 | −16.8 | -- | −10.5 | -- |
Oral Study 3 | ||||||
10 mg/day olanzapine (vs. placebo) | 50 | 10.0 | −12.3 | .71 (moderate) | −7.7 | .60 (moderate) |
10 mg/day olanzapine (vs. 1 mg) | 50 | 10.0 | −12.3 | .48 (moderate) | −7.7 | .45 (moderate) |
1 mg/day olanzapine (vs. placebo) | 52 | 1.0 | −1.9 | .22 (moderate) | −2.0 | .14 (small) |
Placebo | 50 | 0.0 | 2.8 | -- | −0.2 | -- |